GPCR
insider transactionsStructure Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-34.9K
0 buy · 34.9K sell
Net value · 365d
-$2.4M
$0 in · $2.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
10
0 buy · 34.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
39.5K sh
Own New
-
Grant·A
Director
$0
39.5K sh
Own New
-
Grant·A
Director
$0
39.5K sh
Own New
-
Grant·A
Director
$0
39.5K sh
Own New
-
Grant·A
COO & GC
$0
223.8K sh
Own New
-
Grant·A
COO & GC
$0
184.6K sh
Own New
-
Sell·S
Other, 10% Owner
$885.8K
16.1K sh · $55.07
Own -33%
-
Sell·S
Other, 10% Owner
$75.3K
1.4K sh · $55.07
Own -33%
-
Grant·A
Jun Yoon KEY
CHIEF FINANCIAL OFFICER
$0
128.9K sh
Own New
-
Grant·A
Jun Yoon KEY
CHIEF FINANCIAL OFFICER
$0
104.1K sh
Own +8%
-
Grant·A
CHIEF EXECUTIVE OFFICER
$0
322.2K sh
Own New
-
Grant·A
CHIEF EXECUTIVE OFFICER
$0
260.2K sh
Own +23%
-
Grant·A
CHIEF TECHNOLOGY OFFICER
$0
40.3K sh
Own New
-
Grant·A
CHIEF TECHNOLOGY OFFICER
$0
32.5K sh
Own +30%
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$0
53.7K sh
Own New
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$0
43.4K sh
Own +23%
-
Grant·A
Chief Development Officer
$0
59.1K sh
Own New
-
Grant·A
Chief Development Officer
$0
47.7K sh
Own +44%
-
Grant·A
CHIEF MEDICAL OFFICER
$0
94.0K sh
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
75.9K sh
Own +37%
-
Other·F
Jun Yoon KEY
CHIEF FINANCIAL OFFICER
$468.2K
22.3K sh · $20.99
Own -2%
-
Other·F
CHIEF EXECUTIVE OFFICER
$1.1M
53.5K sh · $20.99
Own -4%
-
Other·F
CHIEF TECHNOLOGY OFFICER
$237.5K
11.3K sh · $20.99
Own -10%
-
Other·F
CHIEF SCIENTIFIC OFFICER
$393.2K
18.7K sh · $20.99
Own -9%
-
Other·F
Chief Development Officer
$101.5K
4.8K sh · $20.99
Own -4%
-
Other·F
CHIEF MEDICAL OFFICER
$248.2K
11.8K sh · $20.99
Own -5%
-
Sell·S
Other, 10% Owner
$19.6K
230 sh · $85.04
Own -0%
-
Sell·S
Other, 10% Owner
$547.3K
6.5K sh · $84.22
Own -12%
-
Sell·S
Other, 10% Owner
$323.4K
3.9K sh · $83.35
Own -7%
-
Sell·S
Other, 10% Owner
$449.7K
5.5K sh · $82.10
Own -9%
-
Sell·S
Other, 10% Owner
$1.7K
20 sh · $85.04
Own -0%
-
Sell·S
Other, 10% Owner
$46.5K
552 sh · $84.22
Own -12%
-
Sell·S
Other, 10% Owner
$27.5K
330 sh · $83.35
Own -7%
-
Sell·S
Other, 10% Owner
$38.2K
465 sh · $82.10
Own -9%
-
Grant·A
CHIEF EXECUTIVE OFFICER
$0
824 sh
Own +82%
-
Grant·A
Chief Development Officer
$0
237 sh
Own +105%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Joanne Waldstreicher | Grant A | 39.5K | $0 |
| Jun 17, 2026 | Sharon Tetlow | Grant A | 39.5K | $0 |
| Jun 17, 2026 | Daniel G Welch | Grant A | 39.5K | $0 |
| Jun 17, 2026 | Angus C. Russell | Grant A | 39.5K | $0 |
| Apr 15, 2026 | Matthew Lang | Grant A | 223.8K | $0 |
| Apr 15, 2026 | Matthew Lang | Grant A | 184.6K | $0 |
| Apr 14, 2026 | FMR LLC | Sell S | 16.1K | $885.8K |
| Apr 14, 2026 | FMR LLC | Sell S | 1.4K | $75.3K |
| Mar 19, 2026 | Jun Yoon KEY | Grant A | 128.9K | $0 |
| Mar 19, 2026 | Jun Yoon KEY | Grant A | 104.1K | $0 |
| Mar 19, 2026 | Raymond C Stevens KEY | Grant A | 322.2K | $0 |
| Mar 19, 2026 | Raymond C Stevens KEY | Grant A | 260.2K | $0 |
| Mar 19, 2026 | Yingli Ma | Grant A | 40.3K | $0 |
| Mar 19, 2026 | Yingli Ma | Grant A | 32.5K | $0 |
| Mar 19, 2026 | Xichen Lin | Grant A | 53.7K | $0 |
| Mar 19, 2026 | Xichen Lin | Grant A | 43.4K | $0 |
| Mar 19, 2026 | Ashley Hall | Grant A | 59.1K | $0 |
| Mar 19, 2026 | Ashley Hall | Grant A | 47.7K | $0 |
| Mar 19, 2026 | Crespo Blas Coll | Grant A | 94.0K | $0 |
| Mar 19, 2026 | Crespo Blas Coll | Grant A | 75.9K | $0 |
| Mar 3, 2026 | Jun Yoon KEY | Other F | 22.3K | $468.2K |
| Mar 3, 2026 | Raymond C Stevens KEY | Other F | 53.5K | $1.1M |
| Mar 3, 2026 | Yingli Ma | Other F | 11.3K | $237.5K |
| Mar 3, 2026 | Xichen Lin | Other F | 18.7K | $393.2K |
| Mar 3, 2026 | Ashley Hall | Other F | 4.8K | $101.5K |
| Mar 3, 2026 | Crespo Blas Coll | Other F | 11.8K | $248.2K |
| Jan 15, 2026 | FMR LLC | Sell S | 230 | $19.6K |
| Jan 15, 2026 | FMR LLC | Sell S | 6.5K | $547.3K |
| Jan 15, 2026 | FMR LLC | Sell S | 3.9K | $323.4K |
| Jan 15, 2026 | FMR LLC | Sell S | 5.5K | $449.7K |
| Jan 15, 2026 | FMR LLC | Sell S | 20 | $1.7K |
| Jan 15, 2026 | FMR LLC | Sell S | 552 | $46.5K |
| Jan 15, 2026 | FMR LLC | Sell S | 330 | $27.5K |
| Jan 15, 2026 | FMR LLC | Sell S | 465 | $38.2K |
| Nov 20, 2025 | Raymond C Stevens KEY | Grant A | 824 | $0 |
| Nov 20, 2025 | Ashley Hall | Grant A | 237 | $0 |
About GPCR insider trading
This page tracks insider transactions for Structure Therapeutics Inc. (GPCR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.